Memphasys Ltd Implements Leadership Restructure to Support Global Commercialisation of Felix™ System
Memphasys Ltd (ASX: MEM) has announced a leadership restructure aimed at supporting its direct-selling global commercialisation strategy for the Felix™ System. As part of this change, the CEO position has been made redundant, and Dr. David Ali will depart the company, effective 31 December 2025. The Board thanked Dr. Ali for his contributions, particularly in strengthening the company’s commercial readiness and advancing regulatory efforts.
Memphasys is progressing towards the commercial rollout of the Felix™ System, with CE Mark approval imminent, unlocking significant opportunities in Europe. The company is now focusing on a Go-Direct commercial strategy, which has already seen success in the Middle East, Turkey, and India. This model will allow Memphasys to directly manage customer engagement, pricing, and clinical deployment. Resources previously allocated to the CEO role will be redirected to expand the Business Development team, focusing on priority markets such as Europe, MENA, and India.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to this. Read our Privacy Policy and Terms & Conditions
Memphasys Ltd Implements Leadership Restructure to Support Global Commercialisation of Felix™ System
Memphasys Ltd (ASX: MEM) has announced a leadership restructure aimed at supporting its direct-selling global commercialisation strategy for the Felix™ System. As part of this change, the CEO position has been made redundant, and Dr. David Ali will depart the company, effective 31 December 2025. The Board thanked Dr. Ali for his contributions, particularly in strengthening the company’s commercial readiness and advancing regulatory efforts.
Memphasys is progressing towards the commercial rollout of the Felix™ System, with CE Mark approval imminent, unlocking significant opportunities in Europe. The company is now focusing on a Go-Direct commercial strategy, which has already seen success in the Middle East, Turkey, and India. This model will allow Memphasys to directly manage customer engagement, pricing, and clinical deployment. Resources previously allocated to the CEO role will be redirected to expand the Business Development team, focusing on priority markets such as Europe, MENA, and India.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au